0000000000466735

AUTHOR

Nina Friis-moller

0000-0002-7449-7393

showing 2 related works from this author

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial inf…

2008

Background. Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. Results. The pro…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAnti-HIV AgentsImmunologyantiretroviral therapyMyocardial Infarction610 Medicine & healthHIV Infections2726 Microbiology (medical)Article10234 Clinic for Infectious DiseasesCoronary artery diseasecardiovascular diseaselipidDiabetes mellitusInternal medicinemedicineHumansHIV InfectionMyocardial infarctionAdverse effectHypolipidemic AgentsHypolipidemic Agentbusiness.industryIncidenceIncidence (epidemiology)Anti-HIV AgentHIV2725 Infectious DiseasesMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious DiseasesFemalebusinessBody mass indexDyslipidemiaHuman
researchProduct

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-co…

2008

Background: Whether nucleoside reverse transcriptase inhibitors increase the risk of myocardial infarction in HIV-infected individuals is unclear. Our aim was to explore whether exposure to such drugs was associated with an excess risk of myocardial infarction in a large, prospective observational cohort of HIV-infected patients. Methods: We used Poisson regression models to quantify the relation between cumulative, recent (currently or within the preceding 6 months), and past use of zidovudine, didanosine, stavudine, lamivudine, and abacavir and development of myocardial infarction in 33 347 patients enrolled in the D:A:D study. We adjusted for cardiovascular risk factors that are unlikely…

AdultMalemedicine.medical_specialtyMyocardial Infarction610 Medicine & healthHIV Infections2700 General MedicinePharmacologyArticle10234 Clinic for Infectious DiseasesZidovudineAbacavirRisk FactorsInternal medicinemedicine80 and overHumansHIV InfectionMyocardial infarctionPoisson DistributionDidanosineAgedAged 80 and overbusiness.industryRisk FactorMedicine (all)StavudineLamivudineGeneral MedicineAbacavir/LamivudineMiddle Agedmedicine.diseaseDideoxynucleosideDideoxynucleosidesReverse Transcriptase InhibitorDidanosineCohortReverse Transcriptase InhibitorsFemalebusinessmedicine.drugHuman
researchProduct